These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38667321)

  • 1. Flow Cytometry-Based Assay to Detect Alpha Galactosidase Enzymatic Activity at the Cellular Level.
    Fekete N; Li LK; Kozma GT; Fekete G; Pállinger É; Kovács ÁF
    Cells; 2024 Apr; 13(8):. PubMed ID: 38667321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy.
    Lenders M; Stappers F; Niemietz C; Schmitz B; Boutin M; Ballmaier PJ; Zibert A; Schmidt H; Brand SM; Auray-Blais C; Brand E
    J Med Genet; 2019 Aug; 56(8):548-556. PubMed ID: 31010832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx Degradation.
    Pollmann S; Scharnetzki D; Manikowski D; Lenders M; Brand E
    Front Immunol; 2021; 12():789142. PubMed ID: 34917096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chaperone Therapy in Fabry Disease.
    Weidemann F; Jovanovic A; Herrmann K; Vardarli I
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease.
    Monticelli M; Hay Mele B; Allocca M; Liguori L; Lukas J; Monti MC; Morretta E; Cubellis MV; Andreotti G
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes.
    Jehn U; Bayraktar S; Pollmann S; Van Marck V; Weide T; Pavenstädt H; Brand E; Lenders M
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease.
    Shiozuka C; Taguchi A; Matsuda J; Noguchi Y; Kunieda T; Uchio-Yamada K; Yoshioka H; Hamanaka R; Yano S; Yokoyama S; Mannen K; Kulkarni AB; Furukawa K; Ishii S
    J Biochem; 2011 Feb; 149(2):161-70. PubMed ID: 20961863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fabry Disease: The Current Treatment Landscape.
    Lenders M; Brand E
    Drugs; 2021 Apr; 81(6):635-645. PubMed ID: 33721270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines.
    Benjamin ER; Flanagan JJ; Schilling A; Chang HH; Agarwal L; Katz E; Wu X; Pine C; Wustman B; Desnick RJ; Lockhart DJ; Valenzano KJ
    J Inherit Metab Dis; 2009 Jun; 32(3):424-40. PubMed ID: 19387866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease.
    Porto C; Pisani A; Rosa M; Acampora E; Avolio V; Tuzzi MR; Visciano B; Gagliardo C; Materazzi S; la Marca G; Andria G; Parenti G
    J Inherit Metab Dis; 2012 May; 35(3):513-20. PubMed ID: 22187137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
    Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
    Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models.
    Besada P; Gallardo-Gómez M; Pérez-Márquez T; Patiño-Álvarez L; Pantano S; Silva-López C; Terán C; Arévalo-Gómez A; Ruz-Zafra A; Fernández-Martín J; Ortolano S
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.
    Stiles AR; Zhang H; Dai J; McCaw P; Beasley J; Rehder C; Koeberl DD; McDonald M; Bali DS; Young SP
    Mol Genet Metab; 2020 Jul; 130(3):209-214. PubMed ID: 32418857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease.
    Lukas J; Cimmaruta C; Liguori L; Pantoom S; Iwanov K; Petters J; Hund C; Bunschkowski M; Hermann A; Cubellis MV; Rolfs A
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.
    Namdar M; Gebhard C; Studiger R; Shi Y; Mocharla P; Schmied C; Brugada P; Lüscher TF; Camici GG
    PLoS One; 2012; 7(4):e36373. PubMed ID: 22558451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human α-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants.
    Yu Y; Mena-Barragán T; Higaki K; Johnson JL; Drury JE; Lieberman RL; Nakasone N; Ninomiya H; Tsukimura T; Sakuraba H; Suzuki Y; Nanba E; Mellet CO; García Fernández JM; Ohno K
    ACS Chem Biol; 2014 Jul; 9(7):1460-9. PubMed ID: 24783948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity.
    Stappers F; Scharnetzki D; Schmitz B; Manikowski D; Brand SM; Grobe K; Lenders M; Brand E
    J Inherit Metab Dis; 2020 Mar; 43(2):334-347. PubMed ID: 31587315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease.
    Hennermann JB; Arash-Kaps L; Fekete G; Schaaf A; Busch A; Frischmuth T
    J Inherit Metab Dis; 2019 May; 42(3):527-533. PubMed ID: 30746723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
    Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
    EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel loss-of-function mutation of the GLA gene in a Chinese Han family with Fabry disease.
    Zhou C; Huang J; Cui G; Zeng H; Wang DW; Zhou Q
    BMC Med Genet; 2018 Dec; 19(1):219. PubMed ID: 30587147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.